Nat Med 18:11701172
doi:10.1371/journal.pone.0326210 Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE
Tirzepatide Next-generation dual-receptor therapy Activates both GLP-1 and GIP receptors delivering superior appetite control and stronger metabolic outcomes than single-pathway medications
In the past year, many telehealth and digital health companies, including Hims & Hers competitor Ro, have jumped into the market, offering prescriptions for GLP-1s as part of an existing weight loss or chronic condition management program or creating a new service line targeting obesity care
One reason may have to do with how trials measure the hormones effectiveness
If you need a provider, call UofL Physicians Primary Care at 502-588-4343 to schedule an appointment